Compare XOMA & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XOMA | FFA |
|---|---|---|
| Founded | 1981 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.6M | 416.1M |
| IPO Year | N/A | N/A |
| Metric | XOMA | FFA |
|---|---|---|
| Price | $32.23 | $21.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $69.50 | N/A |
| AVG Volume (30 Days) | ★ 53.6K | 26.1K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.72% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $47,106,000.00 | N/A |
| Revenue This Year | $88.91 | N/A |
| Revenue Next Year | $13.80 | N/A |
| P/E Ratio | $39.11 | ★ N/A |
| Revenue Growth | ★ 118.02 | N/A |
| 52 Week Low | $18.35 | $15.84 |
| 52 Week High | $39.92 | $19.30 |
| Indicator | XOMA | FFA |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 58.77 |
| Support Level | $31.18 | $20.85 |
| Resistance Level | $32.78 | $21.54 |
| Average True Range (ATR) | 1.53 | 0.29 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 24.73 | 99.92 |
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.